Transcatheter Aortic Valve Implantation with ACURATE
Journal
Journal of interventional cardiology
ISSN: 1540-8183
Titre abrégé: J Interv Cardiol
Pays: United States
ID NLM: 8907826
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
11
2021
revised:
18
03
2022
accepted:
03
05
2022
entrez:
14
7
2022
pubmed:
15
7
2022
medline:
16
7
2022
Statut:
epublish
Résumé
The PROGRESS PVL registry evaluated transcatheter aortic valve implantation (TAVI) in patients treated with ACURATE While clinical outcomes with TAVI are comparable with those achieved with surgery, residual aortic regurgitation (AR) and paravalvular leak (PVL) are common complications. The ACURATE The primary endpoint was the rate of total AR over time, as assessed by a core echocardiographic laboratory. The study enrolled 500 patients (mean age: 81.8 ± 5.1 years; 61% female; mean baseline STS score: 6.0 ± 4.5%) from 22 centers in Europe and Canada; 498 patients were treated with ACURATE The rate of ≥ moderate AR was 4.6% at discharge and 3.1% at 12 months; the rate of ≥ moderate PVL was 4.6% at discharge and 2.6% at 12 months. Paired analyses showed significant improvement in overall PVL between discharge and 12 months ( Results from PROGRESS PVL support the sustained safety and performance of TAVI with the ACURATE
Sections du résumé
Objectives
UNASSIGNED
The PROGRESS PVL registry evaluated transcatheter aortic valve implantation (TAVI) in patients treated with ACURATE
Background
UNASSIGNED
While clinical outcomes with TAVI are comparable with those achieved with surgery, residual aortic regurgitation (AR) and paravalvular leak (PVL) are common complications. The ACURATE
Methods
UNASSIGNED
The primary endpoint was the rate of total AR over time, as assessed by a core echocardiographic laboratory. The study enrolled 500 patients (mean age: 81.8 ± 5.1 years; 61% female; mean baseline STS score: 6.0 ± 4.5%) from 22 centers in Europe and Canada; 498 patients were treated with ACURATE
Results
UNASSIGNED
The rate of ≥ moderate AR was 4.6% at discharge and 3.1% at 12 months; the rate of ≥ moderate PVL was 4.6% at discharge and 2.6% at 12 months. Paired analyses showed significant improvement in overall PVL between discharge and 12 months (
Conclusions
UNASSIGNED
Results from PROGRESS PVL support the sustained safety and performance of TAVI with the ACURATE
Identifiants
pubmed: 35832535
doi: 10.1155/2022/9138403
pmc: PMC9252754
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9138403Informations de copyright
Copyright © 2022 Won-Keun Kim et al.
Déclaration de conflit d'intérêts
Dr. Kim reports personal fees from Boston Scientific, Edwards Lifesciences, Abbott, Medtonic, and Meril, outside the submitted work. Dr. Thiele has nothing to disclose. Dr. Linke reports grants from Novartis and Edwards Lifesciences, personal fees from Medtronic, Abbott, Edwards Lifesciences, Boston Scientific, Astra Zeneca, Novartis, Pfizer, Abiomed, Bayer, and Boehringer, and other from Picardia, Transverse Medical, and Claret Medical, outside the submitted work. Dr. Kuntze reports grants from Edwards, outside the submitted work. Dr. Fichtlscherer has nothing to disclose. Dr. Webb reports personal fees from Edwards Lifesciences, outside the submitted work. Dr. Chu reports personal fees from Medtronic, Edwards Lifesciences, Boston Scientific, Abbott Vascular, Terumo Aortic, and Cryolife, outside the submitted work. Dr. Adam reports grants and personal fees from Medtronic and personal fees from Boston Scientific and Edwards Lifesciences, outside the submitted work. Dr Schymik has nothing to disclose. Dr. Geisler reports grants from Edwards Lifesciences and Medtronic, outside the submitted work. Dr. Kharbanda reports grants and personal fees from Boston Scientific, outside the submitted work. Drs. Christen and Allocco are employees and shareholders of Boston Scientific.
Références
J Am Coll Cardiol. 2014 May 20;63(19):1972-81
pubmed: 24657695
N Engl J Med. 2014 May 8;370(19):1790-8
pubmed: 24678937
JACC Cardiovasc Interv. 2014 Sep;7(9):1022-32
pubmed: 25234675
J Clin Med. 2021 Oct 09;10(20):
pubmed: 34682750
Circulation. 2021 Mar 23;143(12):1267-1269
pubmed: 33750210
J Thorac Cardiovasc Surg. 2016 Sep;152(3):783-90
pubmed: 27321435
Circulation. 2020 Dec 22;142(25):2431-2442
pubmed: 33054367
Eur Heart J. 2015 Feb 14;36(7):449-56
pubmed: 25273886
JACC Cardiovasc Interv. 2009 Sep;2(9):821-7
pubmed: 19778769
JACC Cardiovasc Interv. 2015 Dec 21;8(14):1797-806
pubmed: 26718510
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Int J Cardiovasc Imaging. 2015 Oct;31(7):1461-8
pubmed: 26187523
J Am Coll Cardiol. 2015 May 26;65(20):2184-94
pubmed: 25787196
JAMA Cardiol. 2017 Nov 1;2(11):1208-1216
pubmed: 28973091
EuroIntervention. 2017 Oct 13;13(9):e1040-e1046
pubmed: 28804056
Catheter Cardiovasc Interv. 2016 Jan 1;87(1):165-75
pubmed: 26425793
EuroIntervention. 2018 Feb 02;13(15):e1764-e1770
pubmed: 29131801
N Engl J Med. 2012 May 3;366(18):1686-95
pubmed: 22443479
Clin Res Cardiol. 2021 Dec;110(12):1912-1920
pubmed: 34148125
Am J Cardiol. 2020 Sep 15;131:12-16
pubmed: 32622500
JAMA. 2014 Apr 16;311(15):1503-14
pubmed: 24682026
EuroIntervention. 2013 Sep 10;9 Suppl:S107-10
pubmed: 24025946
Circulation. 2016 Jul 12;134(2):130-40
pubmed: 27400898
Eur Heart J. 2012 Apr;33(8):969-76
pubmed: 22240494
Pacing Clin Electrophysiol. 2021 Feb;44(2):410-415
pubmed: 33373045
JACC Cardiovasc Interv. 2018 Sep 10;11(17):1721-1729
pubmed: 29803694
Eur Heart J. 2014 Oct 7;35(38):2672-84
pubmed: 24682842
Acta Cardiol Sin. 2020 Mar;36(2):140-147
pubmed: 32201465
Lancet. 2019 Nov 2;394(10209):1619-1628
pubmed: 31570258
Circ Cardiovasc Interv. 2017 Oct;10(10):
pubmed: 28951395
JACC Cardiovasc Interv. 2018 Sep 10;11(17):1669-1679
pubmed: 30190058
Heart. 2011 Jun;97(11):899-906
pubmed: 21398694
JACC Cardiovasc Interv. 2015 Apr 27;8(5):657-69
pubmed: 25946437
JACC Cardiovasc Interv. 2018 Jul 23;11(14):1368-1374
pubmed: 30025731